[Skip to Navigation]
Comment & Response
April 2017

Incorrect Conclusions Concerning Antibiotics and Asthma Exacerbation—Reply

Author Affiliations
  • 1Harvard Medical School, Boston, Massachusetts
  • 2Division of General Internal Medicine and Primary Care, Beth Israel Deaconess Medical Center, Boston, Massachusetts
  • 3Division of General Internal Medicine and Primary Care, Brigham & Women’s Hospital, Boston, Massachusetts
JAMA Intern Med. 2017;177(4):598-599. doi:10.1001/jamainternmed.2017.0113

In Reply The focus of our Invited Commentary1 was on antibiotic stewardship and we did not go into either the details of the AZALEA trial2 nor its generalizability. The single sentence summary of the AZALEA trial2 in our article1 potentially oversimplifies the findings of the study by Johnston and colleagues. However, we respectfully disagree with Johnston and colleagues that our interpretation of their trial2 was inaccurate. Our summary of the AZALEA trial2 was consistent with the brief summary provided by JAMA Internal Medicine that stated, “This randomized clinical trial found no statistically or clinically significant benefit in symptoms, lung function, or speed of recovery.” Brusselle and Van Braeckel stated, “...addition of azithromycin to standard medical care for acute asthma exacerbations did not result in a statistically or clinically significant benefit.”3(p1637)

Add or change institution